Ocular Therapeutix, Inc
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.82%
vs ±13.6% implied · ×0.21
shaded = implied · ▲▼ = realized
Ocular Therapeutix has 1 disclosed supplier and 6 disclosed customers in SEC filings.
SentenceWe have in-licensed a significant portion of our intellectual property from Incept, an intellectual property holding company, under an amended and restated license agreement, or the License Agreement, that we entered into with Incept in January 2012, which was most recently amended in September 2018.
OCUL 10-Kaccession 0001104659-26-010664
SentenceAll of our collaboration revenue was attributable to the performance obligation under our license agreement with AffaMed to conduct a Phase 2 clinical trial of OTX-TIC, which we fully satisfied in 2025.
OCUL 10-Kaccession 0001104659-26-010664
SentenceOur net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery centers, or ASCs, certain hospital outpatient departments, or HOPDs, and certain physicians' offices, and from the direct sale by us to ASCs and physicians' offices, or Direct Sales.
OCUL 10-Kaccession 0001104659-26-010664
SentenceOur net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery centers, or ASCs, certain hospital outpatient departments, or HOPDs, and certain physicians' offices, and from the direct sale by us to ASCs and physicians' offices, or Direct Sales.
OCUL 10-Kaccession 0001104659-26-010664
SentenceFor example, for the years ended December 31, 2025, 2024 and 2023, one in-market customer accounted for approximately 17%, 18%, and 19% of our gross sales of DEXTENZA before adjustments, respectively.
OCUL 10-Kaccession 0001104659-26-010664
SentenceOur net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery centers, or ASCs, certain hospital outpatient departments, or HOPDs, and certain physicians' offices, and from the direct sale by us to ASCs and physicians' offices, or Direct Sales.
OCUL 10-Kaccession 0001104659-26-010664
SentenceOur net product revenue is generated from the sale of DEXTENZA to specialty distributors, or SDs, for resale to certain ambulatory surgery centers, or ASCs, certain hospital outpatient departments, or HOPDs, and certain physicians' offices, and from the direct sale by us to ASCs and physicians' offices, or Direct Sales.
OCUL 10-Kaccession 0001104659-26-010664
Ocular Therapeutix, Inc
6.98
Expected move
Inputs8Q avg ±6.3%·×0.71·cheap
straddle ±14.6%
spot 6.97exp Nov 20ATM strike 7ATM straddle 1.20IV 90%